-
Alectinib (INN), sold
under the
brand name
Alecensa, is an
anticancer medication that is used to
treat non-small-cell lung
cancer (NSCLC). It
blocks the...
- (vemurafenib), to
treat metastatic melanoma caused by BRAF mutation. 2015:
Alecensa (alectinib):
Treatment for non-small cell lung
cancer (NSCLC). 2016: Venclexta...
- for
nausea and vomiting,
licensed by
Eisai Co. and
Helsinn Therapeutics.
Alecensa (alectinib), for ALK-positive non-small cell lung cancer.
Aloxi (palonosetron)...
-
Lymphoma Kinase (ALK) Gene" at ClinicalTrials.gov "Chugai's ALK
Inhibitor "
Alecensa"
Trial Stopped Early for Benefit" (PDF). Roche.
February 2016. Archived...
-
between tumors and
various genes. In 2015, the
United States FDA
approved Alecensa (alectinib) for use in
patients with a
specific type of non-small cell...
- in 2015.,
manufactured by
Genentech and
marketed under the
brand name
Alecensa.
Brigatinib a
second generation targeted therapy (FDA
approved in 2017)...
- 1016/s0140-6736(17)30123-x. PMID 28126333. S2CID 4739527. FDA
approves Alecensa for ALK-positive
metastatic non-small cell lung
cancer Nov 2017 "Novel...
-
trial and
launch of six
cancer medications,
including Gazyva®, Perjeta®,
Alecensa® and Tenctriq®. She has
contributed to, aut****d and
published over 300...
